These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 1728640)
1. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? Dummer R; Posseckert G; Nestle F; Witzgall R; Burger M; Becker JC; Schäfer E; Wiede J; Sebald W; Burg G J Invest Dermatol; 1992 Jan; 98(1):50-4. PubMed ID: 1728640 [TBL] [Abstract][Full Text] [Related]
2. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482 [TBL] [Abstract][Full Text] [Related]
3. Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains. Dummer R; Posseckert G; Sugamura K; Grundmann H; Burg G J Interferon Cytokine Res; 1996 Apr; 16(4):315-20. PubMed ID: 9162525 [TBL] [Abstract][Full Text] [Related]
4. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571 [TBL] [Abstract][Full Text] [Related]
5. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676 [TBL] [Abstract][Full Text] [Related]
6. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Dummer R; Kohl O; Gillessen J; Kägi M; Burg G Arch Dermatol; 1993 Apr; 129(4):433-6. PubMed ID: 8466213 [TBL] [Abstract][Full Text] [Related]
8. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease. Damle RN; Advani SH; Gangal SG Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512 [TBL] [Abstract][Full Text] [Related]
9. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites. Elg SA; Hill RB; Heldman L; Ramakrishnan S Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933 [TBL] [Abstract][Full Text] [Related]
10. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038 [TBL] [Abstract][Full Text] [Related]
11. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. Pizzolo G; Vincenzi C; Vinante F; Rigo A; Veneri D; Chilosi M; Dusi S; Poli G; Zambello R; Semenzato G Cell Immunol; 1992 Apr; 141(1):253-9. PubMed ID: 1555253 [TBL] [Abstract][Full Text] [Related]
12. [Soluble interleukin-2 receptor in patients with urinary bladder cancer]. Wen R; Xie S Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261 [TBL] [Abstract][Full Text] [Related]
13. The role of interleukin 2 (IL-2) and serum-soluble IL-2 receptor cells in idiopathic IgA nephropathy. Parera M; Rivera F; Egido J; Campos A Clin Immunol Immunopathol; 1992 May; 63(2):196-9. PubMed ID: 1351798 [TBL] [Abstract][Full Text] [Related]
14. Leukotriene B4 augments interleukin-2 receptor-beta (IL-2R beta) expression and IL-2R beta-mediated cytotoxic response in human peripheral blood lymphocytes. Stanková J; Gagnon N; Rola-Pleszczynski M Immunology; 1992 Jun; 76(2):258-63. PubMed ID: 1321793 [TBL] [Abstract][Full Text] [Related]
15. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662 [TBL] [Abstract][Full Text] [Related]
16. Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15. Treiber-Held S; Stewart DM; Barraclough HA; Kurman CC; Nelson DL Clin Immunol Immunopathol; 1996 Jul; 80(1):67-75. PubMed ID: 8674241 [TBL] [Abstract][Full Text] [Related]
17. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2: induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity. Yamada S; Ruscetti FW; Overton WR; Herberman RB; Birchenall-Sparks MC; Ortaldo JR J Leukoc Biol; 1987 Jun; 41(6):505-17. PubMed ID: 3110337 [TBL] [Abstract][Full Text] [Related]